Immunotherapy for head and neck cancer: from recurrent/metastatic disease to (neo)adjuvant treatment in surgically resectable tumors

Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III study

(2020) R.L. Ferris et al.   ANNALS OF ONCOLOGY

Immunological effects of nivolumab immunotherapy in patients with oral cavity squamous cell carcinoma

(2020) Ying Xiong et al.   BMC CANCER

Concurrent definitive immunoradiotherapy for patients with Stage III-IV Head and Neck Cancer and Cisplatin contraindication

(2020) Jared Weiss et al.   CLINICAL CANCER RESEARCH

Impact of Neoadjuvant Durvalumab with or without Tremelimumab on CD8+ Tumor Lymphocyte Density, Safety, and Efficacy in Patients with Oropharynx Cancer: CIAO Trial Results

(2020) Renata Ferrarotto et al.   CLINICAL CANCER RESEARCH

Neoadjuvant nivolumab (N) plus weekly carboplatin (C) and paclitaxel (P) in resectable locally advanced head and neck cancer.

(2020) Ralph Zinner et al.   JOURNAL OF CLINICAL ONCOLOGY

SNOW: Sitravatinib and nivolumab in oral cavity cancer (OCC) window of opportunity study.

(2020) Marc Oliva Bernal et al.   JOURNAL OF CLINICAL ONCOLOGY

Quality of Life With Pembrolizumab for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma: KEYNOTE-040

(2020) Kevin J Harrington et al.   JNCI-Journal of the National Cancer Institute

Neoadjuvant and Adjuvant Pembrolizumab in Resectable Locally Advanced, Human Papillomavirus-Unrelated Head and Neck Cancer: A Multicenter, Phase 2 Trial

(2020) Ravindra Uppaluri et al.   CLINICAL CANCER RESEARCH

Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412

(2020) Jean-Pascal Machiels et al.   Future Oncology

LBA40 Neoadjuvant nivolumab and nivolumab plus ipilimumab induce (near-) complete responses in patients with head and neck squamous cell carcinoma: The IMCISION trial

(2020) L. Zuur et al.   ANNALS OF ONCOLOGY

Phase III study of nivolumab alone or combined with ipilimumab as immunotherapy versus standard of care in resectable head and neck squamous cell carcinoma

(2020) Henrike B Zech et al.   Future Oncology

Neoadjuvant Nivolumab or Nivolumab Plus Ipilimumab in Untreated Oral Cavity Squamous Cell Carcinoma

(2020) Jonathan D. Schoenfeld et al.   JAMA Oncology

Safety and efficacy of single cycle induction treatment with cisplatin/docetaxel/ durvalumab/tremelimumab in locally advanced HNSCC: first results of CheckRad-CD8

(2020) Markus Hecht et al.   Journal for ImmunoTherapy of Cancer

Avelumab–cetuximab–radiotherapy versus standards of care in locally advanced squamous-cell carcinoma of the head and neck: The safety phase of a randomised phase III trial GORTEC 2017-01 (REACH)

(2020) Yungan Tao et al.   EUROPEAN JOURNAL OF CANCER

Phase I/II trial of Durvalumab plus Tremelimumab and stereotactic body radiotherapy for metastatic head and neck carcinoma

(2019) Houda Bahig et al.   BMC CANCER

Immune signatures associated with response to neoadjuvant PD-1 blockade in oral cavity cancer.

(2019) Hannah Knochelmann et al.   JOURNAL OF CLINICAL ONCOLOGY

Neoadjuvant presurgical PD-1 inhibition in oral cavity squamous cell carcinoma.

(2019) Joshua Dean Horton et al.   JOURNAL OF CLINICAL ONCOLOGY

Multicenter randomized controlled phase III study of nivolumab alone or in combination with ipilimumab as immunotherapy vs standard follow-up in surgical resectable HNSCC after adjuvant therapy.

(2019) Chia-Jung Busch et al.   JOURNAL OF CLINICAL ONCOLOGY

Nivolumab in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck: Efficacy and Safety in CheckMate 141 by Prior Cetuximab Use

(2019) Robert L. Ferris et al.   CLINICAL CANCER RESEARCH

Nivolumab versus investigator’s choice in patients with recurrent or metastatic squamous cell carcinoma of the head and neck: Efficacy and safety in CheckMate 141 by age

(2019) Nabil F. Saba et al.   ORAL ONCOLOGY

Immuno-radiotherapy with cetuximab and avelumab for advanced stage head and neck squamous cell carcinoma: Results from a phase-I trial

(2019) Joris B.W. Elbers et al.   RADIOTHERAPY AND ONCOLOGY

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

(2019) Barbara Burtness et al.   LANCET

Nivolumab in squamous cell carcinoma of the head and neck

(2018) Pol Specenier   Expert Review of Anticancer Therapy

Optimizing treatments for recurrent or metastatic head and neck squamous cell carcinoma

(2018) Pol Specenier et al.   Expert Review of Anticancer Therapy

Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression

(2018) Robert L. Ferris et al.   ORAL ONCOLOGY

Phase II multi-site investigation of neoadjuvant pembrolizumab and adjuvant concurrent radiation and pembrolizumab with or without cisplatin in resected head and neck squamous cell carcinoma.

(2018) Trisha Michel Wise-Draper et al.   JOURNAL OF CLINICAL ONCOLOGY

Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study

(2018) Ezra E W Cohen et al.   LANCET

Safety and Efficacy of Durvalumab With or Without Tremelimumab in Patients With PD-L1–Low/Negative Recurrent or Metastatic HNSCC

(2018) Lillian L. Siu et al.   JAMA Oncology

Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial

(2017) Kevin J Harrington et al.   LANCET ONCOLOGY

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

(2016) Robert L. Ferris et al.   NEW ENGLAND JOURNAL OF MEDICINE